Trial Profile
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 0p-1-2
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Bronchiolitis obliterans
- Focus Therapeutic Use
- Acronyms INFINITx-BOS
- 02 May 2022 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 02 May 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.
- 11 May 2021 On October 15th 2020, 14 patients were already included.